Christopher Rovaldi - 18 Feb 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Chief Operating Officer
Issuer ticker: KROS
Reported as of: 18 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2025, 16:15:13 UTC
Prior SEC filing: 15 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Keith Regnante, Attorney-in-Fact

Key filing fact

Christopher Rovaldi filed Form 4 for Keros Therapeutics, Inc. (KROS) on 19 Feb 2025.

Key facts

This page summarizes Christopher Rovaldi's Form 4 filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Feb 2025, 16:15.

Change

Previous filing in this sequence was filed on 15 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KROS transaction

Common Stock

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 18 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date.